Loading...

Fennec Pharmaceuticals Inc.

FRX.TOTSX
Healthcare
Biotechnology
CA$11.94
CA$0.49(4.28%)

Fennec Pharmaceuticals Inc. (FRX.TO) Stock Competitors & Peer Comparison

See (FRX.TO) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
FRX.TOCA$11.94+4.28%328.1M-19.26-CA$0.62N/A
BLU.TOCA$19.48-0.10%2.5B-20.29-CA$0.96N/A
MMED.NECA$14.90+9.48%1.1B-4.50-CA$3.31N/A
DRUG.CNCA$58.56-2.43%414.8M-42.74-CA$1.37N/A
EPRX.TOCA$7.10-1.39%262.6M-6.16-CA$1.19N/A
CYBN.NECA$10.10+5.21%226.8M-1.60-CA$6.15N/A
ONC.TOCA$1.42+2.16%142.3M-3.84-CA$0.37N/A
MSCL.TOCA$0.60+3.45%103.9M2.27CA$0.26N/A
HBP.TOCA$1.35+0.00%100.1M-1.31-CA$1.03N/A
MDNA.TOCA$1.09-2.68%75.6M-6.87-CA$0.16N/A
Showing 1 to 10 of 59 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

FRX.TO vs BLU.TO Comparison August 2025

FRX.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FRX.TO stands at 328.1M. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, FRX.TO is priced at CA$11.94, while BLU.TO trades at CA$19.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FRX.TO currently has a P/E ratio of -19.26, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, FRX.TO's ROE is +6.15%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, FRX.TO is more volatile compared to BLU.TO. This indicates potentially higher risk in terms of short-term price fluctuations for FRX.TO.Check BLU.TO's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;